Eleven patients with clinically definite MS and three healthy controls were investigated by magnetic resonance spectroscopic imaging. The data sets were analysed for all voxels containing white matter only. We classify these voxels in healthy controls as normal white matter (NWM), and in MS patients as normal-appearing white matter unaffected by MS lesions (NAWM) or white matter affected by MS lesions. The spectra belonging to the voxels were analysed for content of cholines, creatines and N-ocetylasportote (NAA), and compared as a group. It was found that lesions differ from white matter in chemical composition and, moreover, that normal-appearing white matter differs from healthy white matter. Specifically, levels of NAA are lower in patients. There seems to be a linear relation between the composition of white matter and the expanded disability status scale value for the patient The presence of lactate could not be established, and no unambiguous differences were found between patients with relapsing-remitting and relapsing-progressive disease.
1 Paty DW, et al. (1986) Magnetic resonance imaging (MRI) in multiple sclerosis (MS): a serial study in relapsing and remitting patients with quantitative measurements of lesion size.Neurology36 (suppl. 1): 177.
2.
2 Kermode AG, et al. (1990) Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology40: 229–235.
3.
3 Truyen L, et al. (1990) Improved correlation of magnetic resonance imaging (MRI) with clinical status in multiple sclerosis (MS) by use of an extensive standardized imaging-protocol. J Neurol Sciences96: 173–182.
4.
4 Minderhoud JM, et al. (1992) In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis. Arch Neurol49: 161–165.
5.
5 Arnold DL, et al. (1990) Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med.14: 154–159.
6.
6 Arnold DL, et al. (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol36: 76–82.
7.
7 Matthews PM, et al. (1991) Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology41: 1251–1256.
8.
8 Poser CM, et al. (1983) New diagnostic criteria for MS. Ann Neurol.13: 227–231.
9.
9 den Boer JA, et al. (1993) Multislice turbo-FLAIR in brain studies of multiple sclerosis. Abstract 328. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
10.
10 Bottomley PA. (1987) Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci508: 333–348.
11.
11 Ordridge RJ, Cresshull ID. (1986) The correction of transient BO field shifts following the application of pulsed gradients by phase correction in the time domain. J Magn Reson69: 151–155.
12.
12 Davies SEC, et al. (1993) Proton magnetic resonance spectroscopy of postmortem multiple sclerosis brain. Abstract 276. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
13.
13 Pan JW, et al. (1993): Evaluation of multiple sclerosis by high field spectroscopic imaging. Abstract 1552. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
14.
14 's-Gravenmade EJ, et al. (1991) in vivo detection of metabolic abnormalities of MS plaques by means of 1H NMR spectroscopic imaging. In: Current Concepts in Multiple Sclerosis, Wiethölter H, Dichgans J, Merlin J (eds). Elsevier: Amsterdam, pp 47–52.
15.
15 Confort-Gouny S, et al. (1993) A multiparametric data analysis showing the potential of localized proton MR spectroscopy of the brain in the metabolic characterization of neurological diseases. J Neurol Sci118: 123–133.
16.
16 Press WH, et al. (1988), Statistical Description of Data and Modeling of Data. In: Numerical Recipes in C.Cambridge University Press: New York, pp 471–516 and pp 517–565.
17.
17 Christiansen P, Larsson HBW, Henriksen O. (1993) Time dependence of N-acetylaspartate and choline containing compounds in multiple sclerosis. Abstract 279. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
18.
18 Davie CA, et al. (1993) Serial proton MRS in demyelination. Abstract 133. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
19.
19 Doyle T, et al. (1993) Longitudinal, short echo time proton spectroscopic imaging of MS. Abstract 1551. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
20.
20 Jackson EF, Narayama PA, Dyle TJ. (1993) The reproducibility of short echo time 1H spectroscopic imaging studies of human brain. Abstract 130. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
21.
21 Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology33: 1444–1452.
22.
22 Arnold DL, et al. (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol31: 235–241.
23.
23 Davie CA, et al. (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions.Brain, 117: 49–58.
24.
24 Vigneron DB, Moyher SE, Nelson SJ. (1993) High-resolution (0.18cc) proton 3-D chemical shift imaging of the human brain. Abstract 369. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
25.
25 Duyn JH, Moonen CTW. (1993) Fast proton spectroscopic imaging of human brain using multiple spin echoes (Abstract 316). In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
26.
26 Hetherington HP, et al. (1993) High resolution 1H spectroscopic imaging of human brain at high field: quantitative evaluation of gray and white matter metabolite differences. Abstract 127. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
27.
27 Haughton VM, et al. (1992) Quantitative MR in the diagnosis of multiple sclerosis. Magn Reson Med26: 71–78.
28.
28 Husted CA, et al. (1994) Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol36: 157–165.
29.
29 Sinnige LGF, et al. (1995) Correlation between magnetic resonance imaging and clinical parameters in multiple sclerosis.Acta Neurol Scand, accepted for publication.
30.
30 Tas MW, et al. (1993) Patterns of brain MR lesions in subgroups of multiple sclerosis patients. Abstract 1452. In: Proceedings of the Society of Magnetic Resonance in Medicine, 1993: Twelfth Annual Scientific Meeting, Edelman RR (ed.). SMRM: Berkley, CA.
